Regulation & Compliance

A German biotech's novel in vivo CAR T platform uses DNA for durable tumor control, aiming to make advanced cancer therapy an off-the-shelf medicine.

The HLAA 2026 convention showcases AI breakthroughs, policy debates, and the power of community for 50 million Americans with hearing loss.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

Valitor's VLTR-559 shows superior durability in preclinical data, potentially slashing wet AMD treatment from monthly injections to just two per year.

Veteran marketing leader Sandhya G. Davis joins the self-regulation body, a strategic move to bolster consumer trust amid AI and data privacy challenges.

Athene targets the booming RILA market with Amplify 3.0, a new annuity focused on simplification, user control, and expanded downside protection options.

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

GRIN Therapeutics expands its pivotal Phase 3 study for radiprodil to Europe, fueling hope for a first-ever targeted therapy for a rare neurological disorder.

This week's Alert Ready test is more than a drill. It reveals a system's successes, its regional divides, and the private firm at its core.

Spanish CDMO ROIS acquires a major Phoenix facility from Bristol Myers Squibb, securing US drug supply chains and expanding its global footprint.

Ncontracts' new Nquiry platform combines 17 years of data with human experts, promising financial firms fast, defensible answers in a complex regulatory world.

Smart Props Solution's new platform uses blockchain to offer fractional property ownership, aiming to democratize access to real estate passive income.

As demand for emergency cash soars, a new guide tackles misleading terms. But what do 'no credit check' and 'guaranteed approval' really cost you?

A judge denied Cal Coast's bid to force a merger with SDCCU, citing "widespread" compliance failures and making regulatory approval "futile."

A recall of Second Nature's Keto mix for undeclared nuts and cherries is the latest in a series of quality control issues for the snack brand.

Hong Kong-based Infini secures key Canadian regulatory approval, aiming to solve global payment headaches for businesses with its AI and stablecoin platform.

The nation's top infrared sauna franchise celebrates a major milestone, but what's fueling its explosive growth in the multi-billion dollar wellness market?

Democratic fundraising giant ActBlue files a federal lawsuit against Texas AG Ken Paxton, claiming a politically motivated attack on its constitutional rights.

Consumers and insurers who bought QVAR inhalers may get cash from a $35M settlement over claims Teva illegally blocked cheaper generic alternatives.

The K-beauty brand expands into Mexico's booming market, but safety claims face scrutiny as reports of adverse effects surface in other regions.